A phase II study (NCT03040986) showed that patients with advanced pancreatic cancer harboring somatic KRASG12R mutation were more sensitive to Selumetinib, a mitogen-activated protein kinase 1 and 2 inhibitor,24similar to our study reported. This evidence concerns the gene MAP2K1 and familial pancreatic carcinoma.